ES2151557T3 - Corpusculos de proteinas de estaño, estanniocalcina. - Google Patents

Corpusculos de proteinas de estaño, estanniocalcina.

Info

Publication number
ES2151557T3
ES2151557T3 ES94923154T ES94923154T ES2151557T3 ES 2151557 T3 ES2151557 T3 ES 2151557T3 ES 94923154 T ES94923154 T ES 94923154T ES 94923154 T ES94923154 T ES 94923154T ES 2151557 T3 ES2151557 T3 ES 2151557T3
Authority
ES
Spain
Prior art keywords
fcf
revealed
polypeptide
estanniocalcina
corpuscles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94923154T
Other languages
English (en)
Inventor
Henrik Olsen
Mark D Adams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Application granted granted Critical
Publication of ES2151557T3 publication Critical patent/ES2151557T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/834—Urine; urinary system
    • Y10S530/835—Kidney

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE REVELAN POLIPEPTIDOS FCF-10 HUMANOS Y ADN (ARN) QUE CODIFICAN DICHOS POLIPEPTIDOS FCF-10. TAMBIEN SE SUMINISTRA UN PROCEDIMIENTO PARA LA PRODUCCION DE DICHO POLIPEPTIDO POR TECNICAS DE RECOMBINACION. TAMBIEN SE REVELAN METODOS PARA LA UTILIZACION DE DICHO POLIPEPTIDO PARA ESTIMULAR LA VASCULARIZACION, PARA TRATAR HERIDAS Y EVITAR DAÑOS NEURONALES. TAMBIEN SE REVELAN ANTAGONISTAS CONTRA DICHO POLIPEPTIDO Y SU USO COMO UN TERAPEUTICO PARA EVITAR LA PROLIFERACION CELULAR ANORMAL, TRASTORNOS HIPERVASCULARES Y LA PROLIFERACION DE CELULAS EPITELIALES. TAMBIEN SE REVELAN METODOS DE DIAGNOSTICO PARA DETECTAR MUTACIONES EN LA SECUENCIA CIFRADA DE FCF-10 Y ALTERACIONES EN LA CONCENTRACION DE PROTEINA DE FCF-10 EN UNA MUESTRA DERIVADA DE UN HUESPED.
ES94923154T 1994-03-08 1994-05-09 Corpusculos de proteinas de estaño, estanniocalcina. Expired - Lifetime ES2151557T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/208,005 US5837498A (en) 1994-03-08 1994-03-08 Corpuscles of stannius protein, stanniocalcin

Publications (1)

Publication Number Publication Date
ES2151557T3 true ES2151557T3 (es) 2001-01-01

Family

ID=22772838

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94923154T Expired - Lifetime ES2151557T3 (es) 1994-03-08 1994-05-09 Corpusculos de proteinas de estaño, estanniocalcina.

Country Status (15)

Country Link
US (5) US5837498A (es)
EP (1) EP0750626B1 (es)
JP (1) JP3687974B2 (es)
KR (1) KR100338583B1 (es)
CN (2) CN1560080A (es)
AT (1) ATE197155T1 (es)
AU (1) AU684297B2 (es)
CA (1) CA2184905A1 (es)
DE (1) DE69426209T2 (es)
DK (1) DK0750626T3 (es)
ES (1) ES2151557T3 (es)
GR (1) GR3035099T3 (es)
PT (1) PT750626E (es)
WO (1) WO1995024411A1 (es)
ZA (1) ZA943702B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837498A (en) * 1994-03-08 1998-11-17 Human Genome Scienes, Inc. Corpuscles of stannius protein, stanniocalcin
AU687962B2 (en) * 1994-11-10 1998-03-05 Human Genome Sciences, Inc. Human stanniocalcin-alpha
US6008322A (en) * 1996-04-02 1999-12-28 Zymogenetics, Inc. Stanniocalcin-2
TW474945B (en) * 1997-12-26 2002-02-01 Daiichi Seiyaku Co Peptide derivatives having analgesic activity and capable of orally admistration
ATE311197T1 (de) * 1998-09-17 2005-12-15 Daiichi Seiyaku Co Heilmittel und/oder vorbeugungsmittel gegen fettleibigkeit
CA2387685A1 (en) * 1999-10-27 2001-05-03 Human Genome Sciences, Inc. Stanniocalcin proteins and nucleic acids and methods based thereon
US6902890B1 (en) * 1999-11-04 2005-06-07 Diadexus, Inc. Method of diagnosing monitoring, staging, imaging and treating cancer
US20040254102A1 (en) * 2000-07-11 2004-12-16 Yuji Yoshiko Remedies for bone diseases
US20040009171A1 (en) * 2001-10-18 2004-01-15 Genentech, Inc. Methods for the treatment of carcinoma
CA2463492A1 (en) * 2001-10-18 2003-04-24 Genentech, Inc. Methods for the treatment of carcinoma
US7056685B1 (en) 2002-11-05 2006-06-06 Amgen Inc. Receptor ligands and methods of modulating receptors
US8759298B2 (en) 2010-05-03 2014-06-24 Scott & White Healthcare Protein therapy for corneal inflammation, epithelial wound healing, and photoreceptor degeneration

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5447841A (en) * 1986-01-16 1995-09-05 The Regents Of The Univ. Of California Methods for chromosome-specific staining
WO1988003949A1 (en) * 1986-11-21 1988-06-02 Howard Florey Institute Of Experimental Physiology The cs protein of the corpuscles of stannius
US5491224A (en) * 1990-09-20 1996-02-13 Bittner; Michael L. Direct label transaminated DNA probe compositions for chromosome identification and methods for their manufacture
US5538869A (en) * 1990-12-13 1996-07-23 Board Of Regents, The University Of Texas System In-situ hybridization probes for identification and banding of specific human chromosomes and regions
US5866344A (en) * 1991-11-15 1999-02-02 Board Of Regents, The University Of Texas System Antibody selection methods using cell surface expressed libraries
US5545524A (en) * 1991-12-04 1996-08-13 The Regents Of The University Of Michigan Compositions and methods for chromosome region-specific probes
US5837498A (en) * 1994-03-08 1998-11-17 Human Genome Scienes, Inc. Corpuscles of stannius protein, stanniocalcin

Also Published As

Publication number Publication date
CA2184905A1 (en) 1995-09-14
EP0750626B1 (en) 2000-10-25
AU7310994A (en) 1995-09-25
US5877290A (en) 1999-03-02
CN1178950C (zh) 2004-12-08
CN1143371A (zh) 1997-02-19
KR100338583B1 (ko) 2002-11-14
PT750626E (pt) 2001-03-30
US5837498A (en) 1998-11-17
JPH09511140A (ja) 1997-11-11
ATE197155T1 (de) 2000-11-15
DE69426209T2 (de) 2001-06-07
CN1560080A (zh) 2005-01-05
US20050208552A1 (en) 2005-09-22
US5994301A (en) 1999-11-30
DK0750626T3 (da) 2000-11-20
EP0750626A4 (en) 1997-06-11
US20020146791A1 (en) 2002-10-10
JP3687974B2 (ja) 2005-08-24
WO1995024411A1 (en) 1995-09-14
ZA943702B (en) 1995-11-27
EP0750626A1 (en) 1997-01-02
DE69426209D1 (de) 2000-11-30
US7326537B2 (en) 2008-02-05
AU684297B2 (en) 1997-12-11
KR970701724A (ko) 1997-04-12
GR3035099T3 (en) 2001-03-30

Similar Documents

Publication Publication Date Title
MX9603897A (es) Factor 10 del crecimiento de los fibroblastos.
BG100771A (en) Hematopoeic protein and ways and methods for its preparation
WO1998030694A3 (en) TUMOR NECROSIS FACTOR RECEPTORS 6α AND 6$g(b)
ES2151557T3 (es) Corpusculos de proteinas de estaño, estanniocalcina.
BRPI0315666B8 (pt) dna de a34 e a33 do tipo 3, proteínas, seus anticorpos e métodos de tratamento usando os mesmos
NZ510367A (en) Interleukin 17-like receptor protein nucleic acid sequence encoding the interleukin receptor protein and method of expressing protein in recombinant vector
DE68929043T2 (de) Für androgen-rezeptor-protein kodierende dna
ATE354638T1 (de) Menschlicher gewebsinhibitor von metalloproteinase-4
ATE294236T1 (de) Promotor der tie rezeptor protein kinase
ATE241639T1 (de) Keratinozyten-wachstumsfaktor 2
ATE382366T1 (de) Modifizierte myelin proteinmoleküle
ATE485377T1 (de) Das überleben dopaminerger neuronen fördernde faktoren und deren verwendungen
AR045671A1 (es) Moleculas de union de nogo a y su uso farmaceutico
WO2002014369A3 (en) Human kininogen d5 domain polypeptides and their use
HUP0001057A2 (hu) A szarvasmarhafélék laktációjával összefüggő fehérje (CD14), az azt kódoló gén és a fehérje B-sejt-aktiválásban való alkalmazása
IT1283899B1 (it) Peptidi e loro usi nella terapia della malattia celiaca
DE69631624D1 (de) Antikörper gegen menschliches restrictin
MX9708493A (es) Factor 15 de crecimiento de fibroblastos.
WO2000060078A3 (en) Latheo encodes a subunit of the origin of recognition complex
MX9706204A (es) Factor 2 de crecimiento de queratinocitos.
MX9706854A (es) Factor 14 de crecimiento de fibroblastos.
WO2002018622A3 (en) TUMOR NECROSIS FACTOR RECEPTORS 6α AND 6$g(b)
NZ333515A (en) Polynucleotide encoding a human chemokine beta-15 use in treatment of thymus related diseases
DE69003216T2 (de) Verwendung von somatostatin.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 750626

Country of ref document: ES